Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials

Endocrine Journal

Volumn 64, Issue 2, 2017, Pages 191-206

  Emoto, Masanori ^a   Oura, Tomonori ^b   Matsui, Akiko ^b   Kazama, Hirotaka ^b   Iwamoto, Noriyuki ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Dulaglutide; Glp 1 receptor agonist; Japanese; Pancreatitis; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLASE; BIGUANIDE DERIVATIVE; DULAGLUTIDE; GLITAZONE DERIVATIVE; INSULIN GLARGINE; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PANCREAS ENZYME; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ACUTE PANCREATITIS; ADULT; ARTICLE; CLINICAL STUDY; DRUG SAFETY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ACUTE DISEASE; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; JAPAN; MIDDLE AGED; MULTICENTER STUDY; PANCREAS; PANCREATITIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; JAPAN; MALE; MIDDLE AGED; PANCREAS; PANCREATITIS; RECOMBINANT FUSION PROTEINS;

EID: 85014039439     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ16-0365     Document Type: Article

References (34)

1. Azoulay L (2015) Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Diabetes Care 38: 951-953.
2. Gale EA (2015) Smoke or fire? Acute pancreatitis and the liraglutide trials. Diabetes Care 38: 948-950.
3. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150-156.
4. Dore DD, Seeger JD, Arnold Chan K (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25: 1019-1027.
5. Garg R, Chen W, Pendergrass M (2010) Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care 33: 2349-2354.
6. Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, et al. (2015) Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care 38: 1089-1098.
7. Jensen TM, Saha K, Steinberg WM (2015) Is there a link between liraglutide and pancreatitis? a post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 38: 1058-1066.
8. Meier JJ, Nauck MA (2014) Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 57: 1320-1324.
9. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, et al. (2014) Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 370: 794-797.
10. Nakamura T, Ito T, Uchida M, Hijioka M, Igarashi H, et al. (2014) PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. Lab Invest 94: 63-78.
11. Nakata H, Sugitani S, Yamaji S, Otsu S, Higashi Y, et al. (2012) Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologi-cally in two cases of diabetic patients with end-stage renal disease. Intern Med 51: 3045-3049.
12. Sue M, Yoshihara A, Kuboki K, Hiroi N, Yoshino G (2013) A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin Med Insights Case Rep 6: 23-27.
13. Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, et al. (2012) Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS One 7: e53224.
14. Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, et al. (2016) Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig 7: 565-573.
15. Dungan KM, Povedano ST, Forst T, Gonzalez JG, Atisso C, et al. (2014) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet 384: 1349-1357.
16. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, et al. (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2: 289-297.
17. Nauck MA, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, et al. (2014) Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 37: 2149-2158 (Erratum in: Diabetes Care 38: 538).
18. Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, et al.; LEADER Trial investigators (2014) LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 43: 1223-1231.
19. Hameed AM, Lam VW, Pleass HC (2015) Significant elevations of serum lipase not caused by pancreatitis: A systematic review. HPB (Oxford) 17: 99-112.
20. Trulicity [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company 2015. Available at http://pi.lilly.com/us/trulicity-uspi.pdf Accessed 6 July 2016.
21. Trulicity [Summary of Product Characteristics]. Houten, The Netherlands: Eli Lilly and Company 2015. Available at http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002825/WC500179470.pdf Accessed 6 July 2016.
22. Trulicity Ateos [Japan package insert]. Hyogo Japan: Eli Lilly Japan K.K. 2016. Available at http://www.info.pmda.go.jp/downfiles/ph/PDF/530471_ 2499416G1029_1_07.pdf (In Japanese) Accessed 6 Feb 2017.
23. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, et al. (2014) Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 37: 2159-2167 (Erratum in: Diabetes Care 38: 1393-1394).
24. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, et al. (2015) Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab 17: 974-983.
25. Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, et al. (2016) Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases gly-cated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab 18: 249-257.
26. Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, et al. (2015) Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or big-uanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab 17: 994-1002.
27. Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, et al. (2015) A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocr J 62: 1101-1114.
28. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC (2011) Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 106: 1697-1704.
29. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, et al. (2016) Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med 176: 1464-1473.
30. Nishizawa M, Nakabayashi H, Uehara K, Nakagawa A, Uchida K, et al. (2013) Intraportal GLP-1 stimulates insulin secretion predominantly through the hepa-toportal-pancreatic vagal reflex pathways. Am J Physiol Endocrinol Metab 305: E376-E387.
31. Linnemann AK, Neuman JC, Battiola TJ, Wisinski JA, Kimple ME, et al. (2015) Glucagon-like peptide-1 regulates cholecystokinin production in β-cells to protect from apoptosis. Mol Endocrinol 29: 978-987.
32. Pandol SJ (2010) The exocrine pancreas. In: Granger DN, Granger JP (ed) Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease. Morgan & Claypool Life Sciences, San Rafael (CA): 1-64. Available at http://www.ncbi.nlm.nih.gov/books/NBK54132 Accessed 19 July 2016.
33. Chandra R, Liddle RA (2009) Neural and hormonal regulation of pancreatic secretion. Curr Opin Gastroenterol 25: 441-446.
34. Eli Lilly and Company. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011- [cited 2 June 2016]. Available at https://clinicaltrials.gov/ct2/show/record/NCT01394952 NLM Identifier: NCT01394952.